Key result
Chronic anabolic steroid use linked to massive AMI and cardiogenic shock in a 26-year-old male.
Why the study?
The association between ischemic heart disease and concurrent anabolic androgenic steroid use is underestimated in clinical settings, potentially because patients tend not to disclose its use.
Case Report (n=1)
No
Anabolic androgenic steroid use should be considered as a potential cause of acute myocardial infarction in young, physically active patients without traditional risk factors.
AAS non-disclosure may delay IHD diagnosis in young active patients; this case leaves open population-level risk estimates.
The association between ischemic heart disease (IHD) and the concurrent use of anabolic androgenic steroids (AASs) is underestimated in clinical settings. The tendency of patients to not disclose AASs use may explain this underestimation. In the present case report, the clinical case of a 26-year-old physically active male, who was a physician, without any classical coronary risk factors, who presented with chest pain that was misdiagnosed by the peripheral care unit as skeletal muscle pain is described. Later, the patient was brought to our central hospital (King Abdullah University Hospital) suffering from a massive acute myocardial infarction with marked ECG changes and cardiogenic shock. Following stabilization of his condition, a detailed history of the patient was taken, during which the patient admitted that he was a chronic user of the anabolic steroid sustanon (250 mg, once/week for 6 months) and amino acid supplements (whey protein isolate, 6 tabs every day for 1 year). Specific cardiac markers were increased and the patient exhibited dynamic ischemic changes in his electrocardiogram. Notably, the coronary angiogram of the patient demonstrated ostial occlusion of the left anterior descending artery, which was associated with mid-right coronary artery embolic obstruction. Other than the anabolic steroids and protein supplementation use, the patient history, examination and lab evaluation were normal. During follow up, the patient continued to suffer heart failure with low ejection fraction. In addition, he developed apical thrombus 2 months after primary admission. The patient developed tachycardia in spite of optimal medical treatment and finally received an implantable cardioverter defibrillator. Physicians should always be aware of the possibility of AASs use in young physically active patients. IHD should always be suspected and investigated with typical chest pain in healthy young patients, even if regular risk factors are not present. Medical professionals should not be excluded as potential AASs users/abusers.
No takes yet. Share an insight, caveat, or question.
Alrabadi et al. (2020) conducted a case report in Acute myocardial infarction with cardiogenic shock (n=1). Anabolic steroid (sustanon) was evaluated on Clinical presentation of acute myocardial infarction and cardiogenic shock. Chronic use of the anabolic steroid sustanon in a healthy 26-year-old physically active male was associated with a massive acute myocardial infarction complicated by cardiogenic shock.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: